Representative MPFC analysis of AML at diagnosis (upper panels) and MRD1 (lower panels). After sample preparation, cells are labeled with the antibody mixture to identify the backbone leukemic blasts (CD45, CD34, CD117 and CD33, panel A) followed by combinations of fluorochrome-conjugated monoclonal antibodies directed to the leukemic phenotypes (CD38, HLA-DR, CD11b, CD7, CD4, CD56, CD13, CD19, CD11c, CD64, CD133, CD15, NG2, and CD41 (examples in B) at room temperature in the dark. Blast cells are identified by using the gating templates defined at diagnosis. The staining tubes that define the LAIPs at diagnosis are then repeated at the MRD points of study.